C12Y 305/01023
Ceramidase
Official title: Ceramidase (3.5.1.23)
C12Y305/01023 (Ceramidase) appears on 20 US grants and 44 published applications in this corpus.
Search patents in C12Y- Granted patents
- 20
- Published applications
- 44
- Assignees
- 27
- Inventors
- 59
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 2 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 2 |
| 2016 | 1 | 1 |
| 2017 | 0 | 2 |
| 2018 | 2 | 3 |
| 2019 | 2 | 5 |
| 2020 | 3 | 5 |
| 2021 | 3 | 5 |
| 2022 | 0 | 4 |
| 2023 | 3 | 4 |
| 2024 | 2 | 1 |
| 2025 | 0 | 7 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anc80 encoding sphingolipid-metabolizing proteins5 May 2026US 12,618,059 B2Icahn School of Medicine at Mount Sinai
- Modified mammalian cells24 Sep 2024US 12,098,365 B2Genentech, Inc.
- Sphingoid compounds for prophylaxis and/or therapy of a viral infection10 Sep 2024US 12,083,079 B2Harbins Ruhr Bioscience, Inc.
- Oncolytic virus for expression of immune checkpoint modulators10 Oct 2023US 11,779,619 B2Transgene S. A.
- Anc80 encoding sphingolipid-metabolizing proteins for mitigating disease-induced tissue damage4 Apr 2023US 11,618,893 B2Icahn School of Medicine at Mount Sinai
- Modified mammalian cells9 Apr 2026US 2026/0098254 A1Genentech, Inc.
- Treating orthopedic injury with a vector driving expression of acid ceramidase17 Jul 2025US 2025/0228908 A1Icahn School of Medicine at Mount Sinai
- Ceramide levels in the treatment and prevention of infections12 Jun 2025US 2025/0186565 A1Icahn School of Medicine at Mount Sinai
- Novel in vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced hscs for therapy of disorders12 Jun 2025US 2025/0188428 A1The Medical College of Wisconsin, Inc.
- Compositions and methods for treating farber disease29 May 2025US 2025/0170225 A1Icahn School of Medicine at Mount Sinai
Most cited
By later US patents
- Oncolytic virus for expression of immune checkpoint modulators9US 10,555,981 B2Transgene S.A. · 2020
- Sphingoid compounds for prophylaxis and/or therapy of a viral infection2US 10,688,065 B2Harbins Ruhr Bioscience, Inc. · 2020
- Acid ceramidase and mammalian cell survival2US 8,961,962 B2Mount Sinai School of Medicine · 2015